Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [ 18F]EF5

Molecular Imaging and Biology

Volumn 14, Issue 2, 2012, Pages 205-212

  Eskola, Olli ^a   Grönroos, Tove J ^a   Forsback, Sarita ^a   Tuomela, Johanna ^a,d   Komar, Gaber ^a   Bergman, Jörgen ^a,b   Härkönen, Pirkko ^a,c   Haaparanta, Merja ^a   Minn, Heikki ^a   Solin, Olof ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b ÅBO AKADEMI UNIVERSITY   (Finland)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Pharmatest Services Ltd   (Finland)

Author keywords

18F EF5; Biodistribution; Electrophilic synthesis; Hypoxia; Metabolism; PET

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ELECTROPHILICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PURIFICATION; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; TUMOR XENOGRAFT;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; ETANIDAZOLE; FLUORINE RADIOISOTOPES; HUMANS; HYDROCARBONS, FLUORINATED; ISOMERISM; MALE; MICE; RADIOACTIVE TRACERS; RATS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

RATTUS;

EID: 84861481324     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0484-4     Document Type: Article

References (18)

1. Hoogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH (2007) The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. Clin Oncol 19:385-396 (Pubitemid 47007426)
2. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437-447 (Pubitemid 38745529)
3. Varghese AJ, Gulyas S, Mohindra JK (1976) Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res 36:3761-3765
4. Nunn A, Linder K, Strauss HW (1995) Nitroimidazoles and imaging of hypoxia. Eur J Nucl Med 22:265-280
5. Krohn KA, Link JM, Mason RP (2008) Molecular imaging of hypoxia. J Nucl Med 49:129S-148S (Pubitemid 351948041)
6. Minn H, Grönroos TJ, Komar G et al (2008) Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 14:2932-2942
7. Lapi SE, Voller TF, Welch MJ (2009) Positron emission tomography imaging of hypoxia. PET Clin 4:39-47
8. 18F-EF5. Eur J Nucl Med Mol Imaging 30:259-366
9. Koch CJ, Evans SM (2003) Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv Exp Med Biol 510:285-292 (Pubitemid 36307791)
10. Evans SM, Kachur AV, Schiue CY et al (2000) Noninvasive detection of tumour hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41:327-336 (Pubitemid 30091355)
11. 18F]EF3. Eur J Nucl Med Mol Imaging 31:1263-1272
12. 18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 36:209-218
13. 18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54:73-80
14. Bergman J, Solin O (1997) Fluorine-18-labeled fluorine gas for synthesis of tracer molecules. Nucl Med Biol 24:677-683 (Pubitemid 27431992)
15. Laughlin KM, Evans SM, Jenkins WT et al (1996) Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther 277:1049-1057
16. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 49:1-8
17. Evans SM, Koch CJ (2003) Prognostic significance of tumor oxygenation in humans. Cancer Lett 195:1-16 (Pubitemid 36603331)
18. Koch CJ, Hahn SM, Rockwell K, Covey JM, McKenna WG, Evans SM (2001) Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazole-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol 48:177-187 (Pubitemid 32758891)